Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corporation reported Q3 2025 results. Net sales were $133.5 million for the three months ended September 30, 2025, up from $96.7 million a year ago, while net loss narrowed to $16.2 million with basic and diluted net loss per share of $0.28.
Glaucoma products contributed $110.2 million and Corneal Health $23.3 million in the quarter. Gross profit was $104.7 million; operating expenses were $121.1 million, leading to a loss from operations of $16.4 million. Cash and cash equivalents were $98.2 million and short‑term investments $175.5 million at quarter‑end. Total assets were $999.4 million and stockholders’ equity was $769.5 million.
Year to date, net sales reached $364.3 million versus $278.0 million last year, with net loss of $54.0 million. The company closed the Mobius Therapeutics acquisition with $24.5 million consideration and purchased an adjacent Aliso Viejo building for $16.6 million. Accounts receivable rose, driven by iDose TR’s extended payment terms. Shares outstanding were 57,434,740 as of October 29, 2025.
Glaukos Corporation filed a current report describing how it shared its latest quarterly information with investors. On October 29, 2025, the company issued a press release announcing its financial results for the third quarter ended September 30, 2025, which is furnished as Exhibit 99.1. Glaukos also prepared a Quarterly Summary with supplemental business and financial information for the same period, furnished as Exhibit 99.2 and made available in the Financials & Filings section of its investor relations website. The company notes that these materials are furnished, not filed, under securities laws unless later specifically incorporated by reference.
Joseph E. Gilliam, President & COO of Glaukos Corporation (GKOS), reported a transaction on 09/23/2025 where 1,056 shares of common stock were disposed of at $84.69 per share. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations when restricted stock units vested and were delivered (these RSUs were originally granted on March 18, 2021). After the withholding, the reporting person beneficially owns 111,706 shares, of which 62,605 restricted stock units remain unvested and undelivered. The Form 4 is signed by an attorney-in-fact on 09/24/2025.
Glaukos insider sale disclosed: Tomas Navratil, Chief Development Officer, reported multiple dispositions of Glaukos common stock on September 22-23, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted June 12, 2025. Transaction prices ranged from $82.20 to $85.11 (weighted averages reported per block). After the reported transactions, the reporting person beneficially owned 75,907 shares, which include unvested restricted stock units (the filing notes 42,535 RSUs still unvested). Some shares were withheld to satisfy tax withholding upon RSU vesting.
Thomas W. Burns, who serves as Chairman & CEO and a director of Glaukos Corporation (GKOS), reported a disposition of 4,059 shares of common stock on 09/23/2025 at a price of $84.69 per share due to shares withheld for tax obligations upon vesting of previously granted restricted stock units. After the reported transaction, he beneficially owns 150,705 shares directly and holds additional indirect holdings through family and trust vehicles totaling 1,452,039 shares when summing disclosed indirect positions and unvested units: 893,932 (Burns Family Trust), 238,107 (Burns Annuity Trust), 120,000 (Burns Charitable Remainder Trust), 100,000 (Thomas W. Burns Irrevocable Trust), and 100,000 (Janet M. Burns Irrevocable Trust). The filing also notes 87,537 restricted stock units that have not yet vested or been delivered.
Tomas Navratil, Chief Development Officer and director of Glaukos Corporation (GKOS), reported two transactions in September 2025. On 09/18/2025 1,948 shares of common stock were recorded as acquired at no cash price; these shares represent a portion of a restricted stock unit award granted March 18, 2021 that vested after the company determined certain operational targets had been achieved. Fifty percent of those shares will be delivered on 09/23/2025 and the remaining 50% in June 2026. The filing notes withheld shares for tax obligations related to a March 24, 2022 award.
On 09/19/2025 the reporting person disposed of 510 shares at $83.47 per share. After these reported transactions, the filing reports 76,907 shares beneficially owned. The filing is a routine Section 16 Form 4 reflecting vesting and a small sale tied to tax withholding and personal disposition.
Joseph E. Gilliam, President & COO of Glaukos Corporation (GKOS), reported a Form 4 transaction dated 09/18/2025. The filing shows 3,884 shares of common stock were acquired at no cash cost as the result of portion of a 2021 restricted stock unit award becoming earned after the company determined two operational targets were achieved. After the transaction, Mr. Gilliam beneficially owns 112,762 shares, which includes 64,547 restricted stock units still unvested and 167 shares purchased via the ESPP. Half of the newly earned shares will vest and be delivered on 09/23/2025 and the remainder in June 2026. The Form 4 was filed as an individual report.
Thomas W. Burns, Chairman & CEO of Glaukos Corporation (GKOS), reported Form 4 transactions. The filing shows vesting and delivery of restricted stock units after the board committee determined two operational performance targets were achieved. On 09/18/2025, 15,417 shares underlying a 2021 performance RSU award were deemed earned (50% to vest on 09/23/2025; remaining 50% in June 2026). A sale of 1,098 shares occurred on 09/19/2025 at $83.47 per share. The report lists substantial indirect holdings through several family and trust vehicles totaling 1,452,039 shares across named trusts and RSUs that remain unvested.
Form 144 notice for Glaukos Corp (GKOS) reports a proposed sale of 517 restricted common shares by a person whose securities vested on 09/19/2024 and were acquired as compensation. The broker listed is Fidelity Brokerage Services LLC and the aggregate market value of the proposed sale is $43,541.07 with an approximate sale date of 09/22/2025 on the NYSE. The filing also discloses that the same person sold 5,142 common shares on 09/11/2025 for gross proceeds of $453,607.98. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Glaukos Corp (GKOS) insider sale by Chief Development Officer. The filing shows Tomas Navratil sold a total of 5,142 shares on 09/11/2025 under a Rule 10b5-1 trading plan adopted June 12, 2025, at weighted average prices of $87.98 and $88.61. Following these transactions the reporting person beneficially owned 75,469 shares, which include 42,589 restricted stock units that have not vested or been delivered. The filing discloses the sales were executed in multiple trades with price ranges of $87.43–$88.43 and $88.44–$88.88 and states the reporter will provide full trade-by-trade details upon request.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
